Health Economics›Acute myeloid leukemia›Relapsed or refractory subsequent lines of therapy

Relapsed or refractory subsequent lines of therapy

Acute myeloid leukemia · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine, Vorinostat, Gemtuzumab ozogamicin Variant #01 Partial	—	R 100 335	28d	—	—	—	—	—
Ruxolitinib monotherapy Variant #01	—	R 60 650	28d	—	—	—	—	2
Cladribine monotherapy Variant #01	—	R 59 905	5d	—	—	—	—	—
Azacitidine monotherapy Variant #01	—	R 18 699	28d	—	~8.7 mo	—	—	11
Decitabine monotherapy Variant #01	—	R 10 907	42d	—	~6.7 mo	—	—	3
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 3 662	28d	—	7.6 mo	—	—	1
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 172	28d	—	4.7 mo	—	—	1
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	1

8 of 8 regimens shown